Neuphoria Therapeutics Inc (NEUP)

$3.79 +0.02 (0.53%)
Market Cap 20.27M
Revenue (ttm) 15.65M
Net Income (ttm) -370,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.36%
Debt to Equity Ratio 0.00
Volume 20,800
Avg Vol 1,968,836
Day's Range N/A - N/A
Shares Out 5.38M
Stochastic %K 19%
Beta 0.51
Analysts Sell
Price Target $13.50

Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 439 5551
Address:
100 Summit Drive, Burlington, United States
I_am_retail_investor
I_am_retail_investor Dec. 22 at 11:50 PM
$NEUP - merger is more likely than buyout, but hoping for the BO
1 · Reply
LilySanders
LilySanders Dec. 21 at 3:48 PM
$NEUP microcap hugging the floor, first higher low plus sustained buying is the only sign the tide really turned
1 · Reply
guidoschini
guidoschini Dec. 19 at 12:58 PM
$NEUP NEUP is a scam. only down
0 · Reply
JohnTrack
JohnTrack Dec. 18 at 11:34 PM
$NEUP eyes on this trendline...
1 · Reply
JohnTrack
JohnTrack Dec. 18 at 9:24 PM
$NEUP press flare just now!!! https://www.rapidticker.com/news/neup-sec-filing-be9723
0 · Reply
guidoschini
guidoschini Dec. 18 at 12:18 AM
$NEUP NEUP continues to decline in value. Now the path is clear! Always down and worse and worse
0 · Reply
silentarbitrager
silentarbitrager Dec. 17 at 9:55 PM
$NEUP so the Lynx1 directors got voted down. I see this as bullish as removes them as a hostile threat. Leaves the board to pursue value for shareholders without interference from self serving directors. I still think the sum of the parts is double digits here. Let's hope we can get some deals done.
0 · Reply
Hazyviolet
Hazyviolet Dec. 16 at 7:28 PM
$NEUP
1 · Reply
Hazyviolet
Hazyviolet Dec. 16 at 7:17 PM
$NEUP
0 · Reply
Rufusbird
Rufusbird Dec. 16 at 3:39 PM
$NEUP This whole Neuphoria, Linx1, Wainwright 3-way business shows how dirty the small cap stock market can be.
1 · Reply
Latest News on NEUP
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Dec 8, 2025, 8:00 AM EST - 16 days ago

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Dec 4, 2025, 8:00 AM EST - 20 days ago

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Dec 1, 2025, 8:00 AM EST - 23 days ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Nov 24, 2025, 8:00 AM EST - 4 weeks ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Nov 11, 2025, 7:00 AM EST - 6 weeks ago

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Oct 27, 2025, 4:29 PM EDT - 2 months ago

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Oct 21, 2025, 8:16 AM EDT - 2 months ago

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

CTXR PCAR

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Oct 20, 2025, 4:15 PM EDT - 2 months ago

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Sep 29, 2025, 4:54 PM EDT - 3 months ago

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 4:05 PM EDT - 4 months ago

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025, 4:10 PM EDT - 7 months ago

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025, 4:22 PM EDT - 7 months ago

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Apr 15, 2025, 8:00 AM EDT - 9 months ago

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Mar 3, 2025, 7:30 AM EST - 10 months ago

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Feb 12, 2025, 7:00 AM EST - 11 months ago

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Dec 23, 2024, 4:49 PM EST - 1 year ago

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

I_am_retail_investor
I_am_retail_investor Dec. 22 at 11:50 PM
$NEUP - merger is more likely than buyout, but hoping for the BO
1 · Reply
LilySanders
LilySanders Dec. 21 at 3:48 PM
$NEUP microcap hugging the floor, first higher low plus sustained buying is the only sign the tide really turned
1 · Reply
guidoschini
guidoschini Dec. 19 at 12:58 PM
$NEUP NEUP is a scam. only down
0 · Reply
JohnTrack
JohnTrack Dec. 18 at 11:34 PM
$NEUP eyes on this trendline...
1 · Reply
JohnTrack
JohnTrack Dec. 18 at 9:24 PM
$NEUP press flare just now!!! https://www.rapidticker.com/news/neup-sec-filing-be9723
0 · Reply
guidoschini
guidoschini Dec. 18 at 12:18 AM
$NEUP NEUP continues to decline in value. Now the path is clear! Always down and worse and worse
0 · Reply
silentarbitrager
silentarbitrager Dec. 17 at 9:55 PM
$NEUP so the Lynx1 directors got voted down. I see this as bullish as removes them as a hostile threat. Leaves the board to pursue value for shareholders without interference from self serving directors. I still think the sum of the parts is double digits here. Let's hope we can get some deals done.
0 · Reply
Hazyviolet
Hazyviolet Dec. 16 at 7:28 PM
$NEUP
1 · Reply
Hazyviolet
Hazyviolet Dec. 16 at 7:17 PM
$NEUP
0 · Reply
Rufusbird
Rufusbird Dec. 16 at 3:39 PM
$NEUP This whole Neuphoria, Linx1, Wainwright 3-way business shows how dirty the small cap stock market can be.
1 · Reply
I_am_retail_investor
I_am_retail_investor Dec. 14 at 4:58 AM
$NEUP - meant “voted by Dec 11”
0 · Reply
I_am_retail_investor
I_am_retail_investor Dec. 13 at 7:55 PM
$NEUP - voted by Nov 11, now what?
0 · Reply
guidoschini
guidoschini Dec. 11 at 9:08 PM
$NEUP Very bad situation. He loses a lot every day
0 · Reply
guidoschini
guidoschini Dec. 10 at 8:17 PM
$NEUP NEUP unable to react. Always bad
0 · Reply
Mitch___Picks
Mitch___Picks Dec. 10 at 3:16 PM
$NEUP still a swing trade for me. Eventually want to see this hit the gap for 10+, but until then just buy dips and sell rips.
0 · Reply
silentarbitrager
silentarbitrager Dec. 9 at 8:42 PM
$NEUP I always thought Lynx1 were after BNC210 but pretty clear via all the SEC correspondence they want MK-1167 due to the easy potential milestone cashflow and low overheads with Merck on board. The offer barely covers cash backing however and is insulting. I'd have cash backing at $3-$3.50 a share, MK-1167 would be worth at least 4 as a standalone asset and BNC210 is still their best asset and worth at least 4-5 imo. Is a great molecule but stage 3 will be expensive for a chronic indication like PTSD. Hence why they took the throw at the stumps with the SAD trial. Anyhow even in a fire sale the parts are worths double digits $$$ minimum.
0 · Reply
silentarbitrager
silentarbitrager Dec. 9 at 6:32 PM
$NEUP here's hoping Lynx1 prospective directors have been kicked to the curb. Shareholders interest my ass , whilst offering $4.75. Vultures.
0 · Reply
guidoschini
guidoschini Dec. 9 at 5:03 PM
$NEUP NEUP is a dead title!
0 · Reply
silentarbitrager
silentarbitrager Dec. 9 at 4:10 PM
$NEUP any word on AGM shenanigans?
0 · Reply
I_am_retail_investor
I_am_retail_investor Dec. 9 at 12:52 AM
$NEUP - can someone with pockets deeper than mine please squeeze this stock to da moon !?
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 12:55 PM
HC Wainwright & Co. has adjusted their stance on Neuphoria Therapeutics ( $NEUP ), setting the rating to Buy with a target price of 21 → 7.
0 · Reply
JohnTrack
JohnTrack Dec. 4 at 2:34 PM
$NEUP waiting for spark!!
1 · Reply